Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
Twenty five patients with hyperprolactinaemia were treated with pergolide mesylate, a new dopamine receptor agonist. Twenty three received treatment for six to 20 months, and in all serum prolactin concentrations were considerably reduced. In most patients prolactin concentrations were maintained in the normal range by a low, once daily dose of pergolide and reversal of associated reproductive disorders was observed. Tumour volume as assessed by computed tomography decreased considerably during treatment in three out of four patients with a pituitary tumour. The drug was well tolerated. Side effects were similar to those of bromocriptine, but four out of eight patients who had been forced to stop taking bromocriptine because of untoward effects were subsequently able to tolerate treatment with pergolide. Pergolide mesylate promises to be a useful addition to the currently available long acting dopamine agonists in the management of hyperprolactinaemia.
D000328:Adult; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008297:Male; D008599:Menstruation Disturbances / Q000188:drug therapy; D008875:Middle Aged; D010479:Pergolide; D010911:Pituitary Neoplasms / Q000188:drug therapy; D011388:Prolactin / Q000097:blood*; D013997:Time Factors
D004873:Ergolines; D010479:Pergolide; D011388:Prolactin